Search company, investor...

Founded Year

2020

Stage

Series B | Alive

Total Raised

$18.07M

Last Raised

$8.86M | 3 mos ago

About Novorex

Novorex develops therapeutics for cancer and central nervous system diseases through the development of new low-molecular drugs. Its drug development platform uses Fragment-based Drug Discovery (FBDD), which involves screening and optimizing small, low molecular-weight compounds known as fragments. The company was founded in 2020 and is based in Seongnam, South Korea.

Headquarters Location

240 Pangyoyeok-ro, Bundang-gu #302 Samhwan HIPEX A

Seongnam, 13493,

South Korea

Loading...

Loading...

Expert Collections containing Novorex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novorex is included in 1 Expert Collection, including Artificial Intelligence.

A

Artificial Intelligence

11,383 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

Novorex Frequently Asked Questions (FAQ)

  • When was Novorex founded?

    Novorex was founded in 2020.

  • Where is Novorex's headquarters?

    Novorex's headquarters is located at 240 Pangyoyeok-ro, Bundang-gu, Seongnam.

  • What is Novorex's latest funding round?

    Novorex's latest funding round is Series B.

  • How much did Novorex raise?

    Novorex raised a total of $18.07M.

  • Who are the investors of Novorex?

    Investors of Novorex include UTC Investment, Company K Partners, BNH Investment, Hana Ventures, QUAD Investment Management and 10 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.